Let’s glance through the above nutshell that’s showing ATM IVs of G10 pairs which are lower side. Despite a mild pick up in IV rise, all the pairs are still displaying below 8% except USDJPY. This lackluster move is to be deemed as the options writers’ advantage.
Especially, USD rather lost its way in the recent past as Trump opted for continuity in the Fed chair, wage growth cooled to a near two year low, and the publication of the House tax bill did little to inform investors about:
1) The political compromises that will be necessary to pay for tax cuts, and
2) The probability and timeline for tax legislation to pass through Congress.
The Fed and tax were only ever bullish tail-risks for the dollar.
Nevertheless, the removal of uncertainty about the Fed chair and a greater sense of realism about the prospective fiscal/monetary policy mix in the US serve to neutralize the dollar’s immediate tactical prospects.
They also deal yet another blow to USD-based FX vols.
The VXY index of G10 FX volatility is approaching 7% -this is four points beneath the post-Trump peak, three points below its 20Y average, yet still two points above the hole that volatility disappeared into during 2014.
For good measure, the market is realizing even less volatility than the derisory amount VXY prices (delivered volatility of only 7.3% for G10 pairs over the past 3 months).


Indonesia Surprises Markets with Interest Rate Cut Amid Currency Pressure
Mexico's Undervalued Equity Market Offers Long-Term Investment Potential
China's Refining Industry Faces Major Shakeup Amid Challenges
Oil Prices Dip Slightly Amid Focus on Russian Sanctions and U.S. Inflation Data
S&P 500 Relies on Tech for Growth in Q4 2024, Says Barclays
US Gas Market Poised for Supercycle: Bernstein Analysts
Energy Sector Outlook 2025: AI's Role and Market Dynamics
Urban studies: Doing research when every city is different
U.S. Treasury Yields Expected to Decline Amid Cooling Economic Pressures
Fed May Resume Rate Hikes: BofA Analysts Outline Key Scenarios
Gold Cracks Below $4,500 as Safe-Haven Shine Fades; Technical Breakdown Signals Sell-on-Rallies Toward $4,000
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 



